Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS professor addresses genetically modified food in South Africa in inaugural lecture
2016-09-23

Description: Chris Viljoen inaugural lecture Tags: Chris Viljoen inaugural lecture

At the inaugural lecture were, from the left front,
Prof Lis Lange, Vice Rector: Academic;
Prof Chris Viljoen; Prof Gert van Zyl,
Dean: Faculty of Health Sciences; back: Prof Marius Coetzee,
Head of Department of Haematology and Cell Biology;
and Dr Lynette van der Merwe, Undergraduate
Programme Director.
Photo: Stephen Collett

The first genetically modified (GM) crops in South Africa were planted in 1998. Eighteen years later, the country is one of the largest producers of GM food in the world. Those in support of genetically modified crops say this process is the only way to feed a rapidly growing world population. But those who criticise GM food describe it as a threat to the environment and safety of the population. Who is right? According to Prof Chris Viljoen of the Department of Haematology and Cell Biology at the University of the Free State, neither position is well-founded.

GM crops play a vital role in food security

While GM crops have an important role to play in increasing food production, the technology is only part of the solution to providing sufficient food for a growing world population. The major genetically modified crops produced in the world include soybean, cotton, maize and canola. However, the authenticity of food labelling and the long-term safety of GM food are issues that consumers are concerned about.

Safety and labelling of GM food important in South Africa
In his inaugural lecture on the subject “Are you really going to eat that?” Prof Viljoen addressed the importance of the safety and labelling of GM food in the country. “In order for food to be sustainable, production needs to be economically and environmentally sustainable. On the other hand, food integrity, including food quality, authenticity and safety need to be ensured,” Prof Viljoen said. 

Labelling of food products for genetic modification was mandatory in South Africa, he went on to say. “It allows consumers the right of choice whether to eat genetically modified foods or not.” The Consumer Protection Act of 2008 requires food ingredients containing more than 5% of GM content to be labelled. 

GMO Testing Facility world leader in food diagnostic testing
In 1999, Prof Viljoen spearheaded research in developing a GM diagnostic testing platform, and in 2003, a commercial diagnostic platform for GM status certification, called the GMO Testing Facility, was founded. The facility is a licensed Eurofins GeneScan laboratory   a world leader in food diagnostic testing   and provides diagnostic detection and quantification of genetically modified organisms (GMOs) in grain and processed foods for the local and international market.

Molecular diagnostic technology the future of food integrity, authenticity and safety
With GM labelling now well-established in South Africa, the next challenge is to establish the use of molecular diagnostic technology to ensure that food integrity, including food authenticity and safety is maintained, said Prof Viljoen.

“To the question ‘Are you really going to eat that?’ the answer is ‘yes’, but let’s continue doing research to make sure that what we eat is safe and authentic.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept